Decreased blood loss after cardiopulmonary bypass using heparin-coated circuit and 50% reduction of heparin dose.

In a randomized, double-blind study of patients undergoing elective coronary artery grafting, the effect of heparin-coated circuit combined with 50% reduction of systemic heparin bolus was investigated. Ten patients comprised group HC (heparin-coated) and ten group C (controls). The mean total doses of heparin were 172 IU/kg in group HC and 416 IU/kg in group C and the respective protamine doses were 0.96 and 3.96 mg/kg (both p < 0.001). Activated clotting times during cardiopulmonary bypass were significantly shorter in group HC, and both intra- and postoperative bleeding was significantly less than in group C (7.7 vs. 11.7 ml/kg, p = 0.036, and 6.9 vs. 9.7 ml/kg, p = 0.004). Hemoglobin loss via the drains was 22.5 g in group HC and 43.7 g in group C (p < 0.005). Hemolysis at the end of bypass was significantly greater in group C. Apart from one perioperative myocardial infarction in group HC the postoperative course was uneventful. Use of a heparin-coated circuit is concluded to permit complication-free reduction of heparin and protamine doses and to decrease both intra- and postoperative bleeding, which may favorably influence the outcome of coronary artery grafting.

[1]  S. Thelin,et al.  Heparin-coated equipment reduces complement activation during cardiopulmonary bypass in the pig. , 2008, Artificial organs.

[2]  P. Venge,et al.  Heparin-coated circuits reduce activation of granulocytes during cardiopulmonary bypass. A clinical study. , 1992, The Journal of thoracic and cardiovascular surgery.

[3]  W. van Oeveren,et al.  Heparin-coating of extracorporea circuits reduces thrombin formation in patients undergoing cardiopulmonary bypass , 1991 .

[4]  L. Hsu Principles of heparin-coating techniques , 1991 .

[5]  P. Yap Transfusion transmitted viral infections--recent developments in blood donor screening. , 1990, Postgraduate medical journal.

[6]  L. Harker,et al.  Bleeding complications associated with cardiopulmonary bypass. , 1990, Blood.

[7]  H. H. Harris,et al.  Reoperation in the intensive care unit. , 1990, The Annals of thoracic surgery.

[8]  G. Gravlee,et al.  Heparin dosing and monitoring for cardiopulmonary bypass. A comparison of techniques with measurement of subclinical plasma coagulation. , 1990, The Journal of thoracic and cardiovascular surgery.

[9]  B. Polk,et al.  Transmission of Retroviruses by Transfusion of Screened Blood in Patients Undergoing Cardiac Surgery , 1989, The New England journal of medicine.

[10]  M. Salo Immunosuppressive effects of blood transfusion in anaesthesia and surgery , 1988, Acta anaesthesiologica Scandinavica. Supplementum.

[11]  L. Harker Bleeding after cardiopulmonary bypass. , 1986, The New England journal of medicine.

[12]  E. Blackstone,et al.  Effects of protamine administration after cardiopulmonary bypass on complement, blood elements, and the hemodynamic state. , 1986, The Annals of thoracic surgery.

[13]  A. Carpentier,et al.  Deleterious effects of cardiopulmonary bypass. A prospective study of bubble versus membrane oxygenation. , 1985, The Journal of thoracic and cardiovascular surgery.

[14]  H. Al-Mondhiry,et al.  Protamine-Induced Thrombocytopenia and Leukopenia , 1985, Thrombosis and Haemostasis.

[15]  S Westaby,et al.  Complement and the damaging effects of cardiopulmonary bypass. , 1983, Thorax.

[16]  Collins Ja Problems associated with the massive transfusion of stored blood. , 1974 .

[17]  J. van der Linden,et al.  Heparin-coated cardiopulmonary bypass circuits and 25% reduction of heparin dose in coronary artery surgery--a clinical study. , 1992, Upsala journal of medical sciences.

[18]  S. Thelin,et al.  Heparin-coated cardiopulmonary bypass circuits reduce blood cell trauma. Experiments in the pig. , 1991, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[19]  H. Lindberg,et al.  Systemic and pulmonary circulatory effects of protamine following cardiopulmonary bypass in man. , 1991, Scandinavian journal of thoracic and cardiovascular surgery.

[20]  M. Turina,et al.  Reduced blood loss and transfusion requirements with low systemic heparinization: preliminary clinical results in coronary artery revascularization. , 1990, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[21]  D. Vergani,et al.  Complement activation before, during and after cardiopulmonary bypass. , 1990, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[22]  G. Gravlee,et al.  Early anticoagulation peak and rapid distribution after intravenous heparin. , 1988, Anesthesiology.

[23]  P. Venge,et al.  Activation of inflammatory systems during cardiopulmonary bypass. , 1988, Scandinavian journal of thoracic and cardiovascular surgery.

[24]  H. Tydén,et al.  Coagulation, fibrinolysis and bleeding after open-heart surgery. , 1986, Scandinavian journal of thoracic and cardiovascular surgery.

[25]  R. Larsson,et al.  A new non-thrombogenic surface prepared by selective covalent binding of heparin via a modified reducing terminal residue. , 1983, Biomaterials, medical devices, and artificial organs.